PMC:7652766 / 25347-25823 JSONTXT

{"project":"LitCovid-sentences","denotations":[{"id":"T131","span":{"begin":0,"end":476},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A systematic review assessing the clinical outcomes for SARS-CoV-2-infected individuals regarding treatment using angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) concluded that these types of drugs have no deleterious effects and should continue to be used in COVID-19 patients (102), reinforcing the recommendations of several medical societies, including the American Heart Association (103) and European Society of Cardiology (104)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"961","span":{"begin":114,"end":143},"obj":"Gene"},{"id":"962","span":{"begin":287,"end":289},"obj":"Gene"},{"id":"965","span":{"begin":310,"end":318},"obj":"Species"},{"id":"966","span":{"begin":0,"end":1},"obj":"Gene"},{"id":"970","span":{"begin":56,"end":75},"obj":"Disease"},{"id":"971","span":{"begin":301,"end":309},"obj":"Disease"}],"attributes":[{"id":"A961","pred":"tao:has_database_id","subj":"961","obj":"Gene:1636"},{"id":"A962","pred":"tao:has_database_id","subj":"962","obj":"Gene:6999"},{"id":"A965","pred":"tao:has_database_id","subj":"965","obj":"Tax:9606"},{"id":"A966","pred":"tao:has_database_id","subj":"966","obj":"Gene:351"},{"id":"A970","pred":"tao:has_database_id","subj":"970","obj":"MESH:C000657245"},{"id":"A971","pred":"tao:has_database_id","subj":"971","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"A systematic review assessing the clinical outcomes for SARS-CoV-2-infected individuals regarding treatment using angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) concluded that these types of drugs have no deleterious effects and should continue to be used in COVID-19 patients (102), reinforcing the recommendations of several medical societies, including the American Heart Association (103) and European Society of Cardiology (104)."}